{"nctId":"NCT04123561","briefTitle":"Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain","startDateStruct":{"date":"2019-11-26","type":"ACTUAL"},"conditions":["Osteoarthritis of the Knee"],"count":504,"armGroups":[{"label":"TLC599","type":"EXPERIMENTAL","interventionNames":["Drug: TLC599"]},{"label":"Dexamethasone sodium phosphate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TLC599","Drug: DSP"]},{"label":"Normal Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Normal Saline"]}],"interventions":[{"name":"TLC599","otherNames":["TLC599 Injection"]},{"name":"DSP","otherNames":["Dexamethasone Sodium Phosphate"]},{"name":"Normal Saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMale or female ≥40 years of age. BMI ≤ 40 kg/m2. Radiographically documented OA with Kellgren-Lawrence severity Grade 2 or 3 and associated symptoms Patient-reported pain with NRS score ≥4 (on a 0-10 scale) Able to read, understand, and sign the informed consent form, communicate with the investigator, complete study diaries, and understand and comply with protocol requirements.\n\nExclusion Criteria:\n\nRecent use of IA or systemic corticosteroids Patient who is not ambulatory Any surgery or arthroscopy in the index knee within 12 months Any condition that could possibly confound the patient's assessment of index knee pain Substance abuse disorder, or positive urine drug test for illegal drug substances History of acquired or congenital immunodeficiency diseases History of treated malignancy which is disease free for ≤5 years Known allergy or hypersensitivity to the study drugs or their components","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in WOMAC Pain at Week 12 for TLC599 12 mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.968","spread":null},{"groupId":"OG001","value":"-0.798","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 16 for TLC599 12 mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.929","spread":"0.0492"},{"groupId":"OG001","value":"-0.798","spread":"0.0704"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 20 for TLC599 12 mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.873","spread":"0.0489"},{"groupId":"OG001","value":"-0.749","spread":"0.0703"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 24 for TLC599 12mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.845","spread":"0.0496"},{"groupId":"OG001","value":"-0.688","spread":"0.0719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 36 for TLC599 12mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.964","spread":"0.0545"},{"groupId":"OG001","value":"-0.882","spread":"0.0791"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Function at Week 12 for TLC599 12mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.903","spread":"0.0470"},{"groupId":"OG001","value":"-0.735","spread":"0.0681"}]}]}]},{"type":"SECONDARY","title":"PGIC at Week 12 for TLC599 12mg Versus Placebo","description":"Patient Global Impression of Change (PGIC) is a single-item question that measures change in patients' overall improvement rated on a 7-point scale including \"1 = very much improved,\" \"2 = much improved,\" \"3 = minimally improved,\" \"4 = no change,\" \"5 = minimally worse,\" \"6 = much worse,\" or \"7 = very much worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.554","spread":"0.0739"},{"groupId":"OG001","value":"2.791","spread":"0.1059"}]}]}]},{"type":"SECONDARY","title":"Total Rescue Acetaminophen Consumption Through Week 12 for TLC599 12mg Versus Placebo","description":"Rescue medication use of acetaminophen was provided and recorded in electronic patient diaries. Weekly Total Acetaminophen consumption was tabulated for analysis on a weekly basis, starting from the first date of study drug injection: (Day 1, 8), (Day 8, 15), and so on. Average daily use (e.g., Weekly Total Acetaminophen Consumption divided by 7) was computed to produce Weekly Average Daily Acetaminophen Consumption.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.568","spread":"3.1902"},{"groupId":"OG001","value":"29.803","spread":"4.5893"}]}]}]},{"type":"SECONDARY","title":"Durable Responder With ≥30% Decrease in WOMAC Pain From Baseline for Weeks 4 Through 12 for TLC599 12mg Versus Placebo","description":"Durable responder endpoints were derived based on the imputed WOMAC pain data. A subject which has ≥ 30% decrease in pain response from Baseline at each visit within a specified time period (x-y). This was derived for patients based on the Injection 1 Baseline for the following time period (x-y): (4-12).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Function at Week 36 for TLC599 12mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.907","spread":"0.0540"},{"groupId":"OG001","value":"-0.787","spread":"0.0774"}]}]}]},{"type":"SECONDARY","title":"PGIC at Week 36 for TLC599 12mg Versus Placebo","description":"Patient Global Impression of Change (PGIC) is a single-item question that measures change in patients' overall improvement rated on a 7-point scale including \"1 = very much improved,\" \"2 = much improved,\" \"3 = minimally improved,\" \"4 = no change,\" \"5 = minimally worse,\" \"6 = much worse,\" or \"7 = very much worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.635","spread":"0.0883"},{"groupId":"OG001","value":"2.738","spread":"0.1288"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 12 for TLC599 12mg Versus DSP 4 mg","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.968","spread":"0.0467"},{"groupId":"OG001","value":"-0.933","spread":"0.0667"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC Pain at Week 52 for TLC599 12mg Versus Placebo","description":"The WOMAC (Western Ontario \\& McMaster Universities Osteoarthritis Index, Version 3.1) consists of 24 questions rated on a 0-4 Likert scale, totaling a score from 0-96, reflecting the previous 24 hours. Sub-scale scores for Pain (5 items, a 0-20 scale), Stiffness (2 items, a 0-8 scale), and Physical Function (17 items, a 0-68 scale) are summed to calculate the WOMAC Composite score. Both composite and sub-scale scores are normalized to a 0-4 scale for analysis, with higher scores indicating greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.928","spread":"0.0580"},{"groupId":"OG001","value":"-0.934","spread":"0.0820"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":252},"commonTop":["Arthralgia","Back pain","Hypertension","COVID-19","Urinary tract infection"]}}}